EPCAM and neoplasm: The presence of tumor cells in the peripheral blood and ascitic fluid was evaluated by the CellSearch® technology (Veridex LLC, Raritan, NJ), which detects CTCs based on ferrofluids coated with epithelial cell-specific EpCAM antibodies and a mixture of phycoerythrin-conjugated antibodies to CK 8, 18, and 19.